A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet) | MicrobiomeTrials← Back to trialsNCT07613424
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-06-02Est. Completion: 2027-03-31
Enrollment target: 1,000 participants Locations- Research Site, Anyang, China
- Research Site, Baoding, China
- Research Site, Beijing, China
- Research Site, Cangzhou, China
- Research Site, Changzhi, China
- Research Site, Chengdu, China
- Research Site, Chengdu, China
- Research Site, Fuzhou, China
- Research Site, Guangzhou, China
- Research Site, Guangzhou, China
- Research Site, Guangzhou, China
- Research Site, Handan, China
- Research Site, Hefei, China
- Research Site, Huzhou, China
- Research Site, Jinan, China
- Research Site, Jinan, China
- Research Site, Jining, China
- Research Site, Linhai, China
- Research Site, Linyi, China
- Research Site, Lishui, China
- Research Site, Liuzhou, China
- Research Site, Nanchang, China
- Research Site, Nanjing, China
Other microbiome trials you might be interested in
Lung NeoplasmsNeoadjuvant TherapyImmunotherapyMinimal Residual Disease
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (…
Beijing, ChinaEst. completion Oct 31, 2027
Non-small Cell Lung Cancer Stage IV
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non…
Banja Luka, Bosnia and HerzegovinaEst. completion Mar 10, 2026
Research Site, Nanning, ChinaResearch Site, Nantong, ChinaResearch Site, Qiqihar, ChinaResearch Site, Shanghai, ChinaResearch Site, Shanghai, ChinaResearch Site, Shaoxing, ChinaResearch Site, Shenyang, ChinaResearch Site, Shenzhen, ChinaResearch Site, Shijiazhuang, ChinaResearch Site, Shiyan, ChinaResearch Site, Suining, ChinaResearch Site, Taiyuan, ChinaResearch Site, Taiyuan, ChinaResearch Site, Tangshan, ChinaResearch Site, Tianjin, ChinaResearch Site, Tianjin, ChinaResearch Site, Weifang, ChinaResearch Site, Wenzhou, ChinaResearch Site, Wuhan, ChinaResearch Site, Wuhan, ChinaResearch Site, Wuhu, ChinaResearch Site, Wuhu, ChinaResearch Site, Xi'an, ChinaResearch Site, Xiamen, ChinaResearch Site, Xiangyang, ChinaResearch Site, Yangzhou, ChinaResearch Site, Zhoushan, ChinaResearch Site, Zunyi, ChinaNon-small Cell Lung Cancer
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participa…
Bakersfield, United StatesEst. completion Jan 24, 2028